Mohamed Akl, MD
Urogynecology and Reconstructive Pelvic Surgery · Mesa, AZNPI 1154388171
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,000 of the $6,234 with a category attached, or 80.2%. Caldera Medical, Inc accounts for 94.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $5,136 and has fallen 99.1% since, to $48 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in AZ, where the typical reported total is $8,817.
Across 38 payments — averaging $164.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Caldera Medical, Inc$6K
- Astellas Pharma US Inc$191
- Medtronic$51
- Sumitomo Pharma America, Inc.$27
- Boston Scientific$26
- Minerva Surgical, Inc$24
- plus $56 from 3 others
What the payments were for
- Consulting fees$5,00080%
- Food & beverage$1,04617%
- Education$801%
- Gifts$1072%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Caldera Medical, Inc | 22 | $5,859 |
| Astellas Pharma US Inc | 7 | $191 |
| Medtronic(2 entities) | 3 | $51 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Boston Scientific | 1 | $26 |
| Minerva Surgical, Inc | 1 | $24 |
| Femselect Inc. | 1 | $22 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,234 in reported general payments places this provider in the 35th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Arizona.
See all urogynecology and reconstructive pelvic surgery providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 170 | $121,581 |
| GemtesaVibegron | 94 | $64,496 |
| Solifenacin Succinate | 369 | $17,556 |
| ElmironPentosan Polysulfate Sodium | 18 | $12,405 |
| LinzessLinaclotide | 21 | $11,423 |
| Estradiol | 141 | $8,801 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 212 | $5,352 |
| Cephalexin | 185 | $3,817 |
| Heparin SodiumHeparin Sodium,porcine | 37 | $3,389 |
| Methenamine Hippurate | 42 | $2,997 |
| Trimethoprim | 33 | $2,608 |
| Colestipol Hcl | 51 | $2,326 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 251 | $2,138 |
| Clindamycin Phosphate | 31 | $1,809 |
| Oxybutynin Chloride ErOxybutynin Chloride | 91 | $1,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $191 | $121,581170 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $27 | $64,49694 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 24 urogynecology and reconstructive pelvic surgery providers in Arizona.
Other urogynecology and reconstructive pelvic surgery in Mesa
- Kelly KantartzisMesa$21K
- Peter JeppsonMesa$11K
- Ryan StratfordMesa$6K
- Suzette SutherlandScottsdale$354K
- Jennifer KlauschieLitchfield Park$95K
- Gina CliettOro Valley$76K
- Anthony GaddiGilbert$72K
- Felipe VidelaPhoenix$25K
- Daniel StonePhoenix$20K
- Mohammad IslamScottsdale$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.